8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Phase 2

Completed

• Conditions: Autosomal Dominant Polycystic Kidney Disease
• Interventions: Drug: Placebo; Drug: Tolvaptan MR; Drug: Tolvaptan IR

• Registration Number: NCT01451827
• Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Brief Summary

The purpose of this study is to compare the short-term effects of two tolvaptan formulations in patients with ADPKD.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-10
• Study First Submitted: 2011-10-11
• Study First Submitted QC: 2011-10-13
• Study First Posted: 2011-10-14
• Primary Completion: 2013-07
• Study Completion: 2013-07
• Disposition First Submitted: 2014-06-12
• Disposition First Submitted QC: 2014-06-12
• Disposition First Posted: 2014-06-19
• Results First Submitted: 2018-05-21
• Results First Submitted QC: 2018-07-11
• Status Verified: 2018-08
• Results First Posted: 2018-08-13
• Last Update Submitted: 2018-08-30
• Last Update Posted: 2018-09-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 178

Inclusion Criteria

1. Age 18 to 50

2. Subjects with:

   • BMI between 19 and 35 kg/m2

   • diagnosis of ADPKD by modified Ravine criteria:

     • family history: 3cysts/kidney if by sonography or 5 by CT or MRI
     • Without family history: 10 cysts per kidney

   • an eGFR > 45 mL/min/1.73 m2 by the CKD-EPI equation

3. Subjects not planning to become pregnant willing to comply with birth control requirements.

4. Subjects must be in good health as determined by screening tests.

5. Subjects providing informed consent and able to comply with all trial requirements.

Exclusion Criteria

1. Subjects using diuretics within 14 days prior to randomization, or the requirement for intermittent or constant diuretic use for any reason

2. Subjects who had an eGFR < 45 mL/min/1.73 m2 calculated based on the most recent historical creatinine during the last 12 months

3. Subjects with:

   • incontinence, overactive bladder, or urinary retention (eg, BPH), meaning subjects with symptoms of frequent nocturia, as determined by medical history or urinary urgency should be carefully evaluated to exclude non-ADPKD GU issues prior to entry.
   • liver disease, liver function abnormalities, or serology other than that expected for ADPKD with cystic liver disease at baseline
   • a history of renal surgery or cyst drainage within 6 months of randomization
   • blood pressure 150/95 mmHg or < 90/40 mmHg.
   • heart rate outside the range of 40 to 90 bpm.
   • advanced diabetes with a history of poor control, evidence of significant renal disease renal cancer, single kidney, or recent renal surgery
   • other significant medical history that may interfere with the study objectives
   • significant abnormalities in serum sodium concentration (< 135 or > 145 mEq/L)
   • a history of drug and/or alcohol abuse within 2 years prior to screening
   • clinically significant allergic reactions to tolvaptan or chemically related structures such as benzazepines (eg, benzazepril, conivaptan, fenoldopam mesylate, or mirtazapine)

4. Subjects having taken an investigational drug within 30 days preceding randomization on Day 0

5. Subjects taking medications or having concomitant illnesses likely to confound endpoint assessments, including taking approved (ie, marketed) therapies for the purpose of affecting PKD cysts such as tolvaptan, somatostatin agonists (ie, octreotide, sandostatin), Rapamune (sirolimus), anti-sense RNA therapies, other vasopressin antagonists (eg, OPC-31260 [mozavaptan] and Vaprisol® [conivaptan]) or agonists (eg, desmopressin), and cyst reduction surgery

6. Subjects on antihypertensives that have not been on the same antihypertensive regimen for at least 30 days prior to the first dose of IMP

7. Subjects having contraindications to, or interference with, MRI assessments

8. Subjects with a history of serious mental disorders that, in the opinion of the investigator, would exclude the subject from participating in this trial

9. Subjects with previous exposure to tolvaptan

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Placebo MR capsule and 2 placebo IR tablets (8 AM) and 1 placebo IR tablet (4 PM) daily.
Tolvaptan MR 80 mg	Placebo	Tolvaptan MR 80 mg capsule and 2 placebo IR tablets (8 AM) and 1 placebo IR tablet (4 PM) daily.
Tolvaptan MR 50 mg	Tolvaptan MR	Tolvaptan MR 50 mg capsule and 2 placebo IR tablets ( 8 AM) and 1 placebo IR tablet (4 PM) daily.
Tolvaptan MR 50 mg	Placebo	Tolvaptan MR 50 mg capsule and 2 placebo IR tablets ( 8 AM) and 1 placebo IR tablet (4 PM) daily.
Tolvaptan MR 80 mg	Tolvaptan MR	Tolvaptan MR 80 mg capsule and 2 placebo IR tablets (8 AM) and 1 placebo IR tablet (4 PM) daily.
Tolvaptan IR 60/30 mg	Tolvaptan IR	Two tolvaptan IR 30-mg tablets and 1 placebo MR capsule (8 AM) and 1 tolvaptan IR 30-mg tablet (4 PM) daily.
Tolvaptan IR 60/30 mg	Placebo	Two tolvaptan IR 30-mg tablets and 1 placebo MR capsule (8 AM) and 1 tolvaptan IR 30-mg tablet (4 PM) daily.

Primary Outcome Measures

Name	Time	Method
Percent Change From Baseline in Total Kidney Volume (TKV) at Week 3	Baseline to Week 3	The primary endpoint was percent change from baseline in TKV at Week 3. Total kidney volume is an important measure of disease progression. A 3-week time point is adequate to assess acute effects on kidney cyst shrinkage.

Secondary Outcome Measures

Name	Time	Method
Percent Change From Baseline in TKV at Week 8.	Baseline to Week 8	Total kidney volume is an important measure of disease progression. A 3-week time point is adequate to assess acute effects on kidney cyst shrinkage.
Change From Baseline in Total Score of the Autosomal Dominant Polycystic Kidney Disease Urinary Impact Scale (ADPKD-UIS)	Baseline to Week 8	The ADPKD-UIS was a self-administered questionnaire designed to measure ADPKD-related urinary symptoms in participants with ADPKD. This instrument contained 11 items in 3 domains (Urinary Frequency, Urinary Urgency, and Nocturia). Each item was scored using a scale of 1 to 5 (a higher score indicated increased difficulty/extremely bothered). The maximum total score is 55; 1: not difficult/not bothered at all; 55: extremely difficult/extremely bothered.

Trial Locations

Locations (2)

Otsuka Investigational Site; 🇺🇸 Charlottesville, Virginia, United States

Otsuka Investigational Site 2; 🇺🇸 Aurora, Colorado, United States